Clinical Trial Update: Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy and safety of Ropanicant in patients with Major Depressive Disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Ropanicant (Ropanicant)

Snippet

Sponsor: Suven Life Sciences Limited | Conditions: Major Depressive Disorder (MDD) | Phase 2 | Status: COMPLETED